Central Garden & Pet Company (Class A) (CENTA)

Q: What's priced into Central Garden & Pet Company (Class A) (CENTA) stock?

CENTA is classified as cheap versus peers, and the expectations gap is close to neutral. The priced-in assessment is justified, with low fragility, so the evidence does not point to an especially fragile setup based on expectations.

Q: What does the Central Garden & Pet Company (Class A) (CENTA) outlook hinge on?

Over the next few quarters, the thesis depends on management maintaining guidance and continuing to deliver on earnings, alongside disciplined capital spending. Over the multi-year view, the European expansion depends on completing the TRIXIE acquisition and executing it; continued earnings strength at sector peers could also support the backdrop, while weaker employment or a guidance cut would weaken it.

NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-10-23

$39.10+0.75%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Central Garden & Pet Company (Class A)’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q1
Revenue	—	584M
EPS	—	0.13
FY 2026 · Annual
EPS	At least $2.7non-GAAP	—
Capital expenditure	$50M–$60M	—
FY 2027 · Annual
Revenue	—	2.94B
EPS	—	3.142
FY 2028 · Annual
Revenue	—	3.19B
EPS	—	3.321

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
share buybacks and CAPEX near $55M	Profit per share is near $2.7 next quarter.	Intact	CAPEX falls below $50M or buybacks stop next 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS near $2.7 next quarter	Profit per share is near $2.7 next quarter.	Intact	EPS falls below $2.5 next quarter	Diluted EPS: $1.45 per share FY2026-Q3; GAAP. Published target: >=2.7 USD per share. Target period ends 2026-09-30; this observation covers 2026-Q3. Source published Aug 6, 20261.45 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 66f1638c-1e02-4c8e-bfbf-a83a1f75b461. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
net sales growth near 8% YoY	A primary condition in Central Garden & Pet Company (Class A)'s published investment case. The stated target is >=8% YoY.	Intact	YoY revenue growth falls below 5% next 4 quarters	Revenue growth: -8.17% FY2026-Q3; GAAP. Published target: >=8% YoY. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-8.174621 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 66f1638c-1e02-4c8e-bfbf-a83a1f75b461. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
PE ratio below 13	A supporting condition in Central Garden & Pet Company (Class A)'s published investment case. The stated target is <=13 PE TTM.	Intact	PE ratio rises above 17.5 next 4 quarters	P/E (TTM): 13.25x As of 2026-10-23; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 23, 202613.2542 ratio · calculatedLast status assessment Oct 24, 2026 Measurement source consolidated · TTM valuation Period ending Oct 23, 2026 Source: mart.stock_valuation_daily. Reference: CENTA:2026-10-23. Source status: canonical calculation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-27 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-28	Unavailable	Unavailable	2 / 1
2026-09-29	Unavailable	Unavailable	2 / 1
2026-09-30	Unavailable	Unavailable	2 / 1
2026-10-01	Unavailable	Unavailable	2 / 1
2026-10-02	Unavailable	Unavailable	2 / 1
2026-10-03	Unavailable	Unavailable	2 / 1
2026-10-04	Unavailable	Unavailable	2 / 1
2026-10-05	Unavailable	Unavailable	2 / 1
2026-10-06	Unavailable	Unavailable	2 / 1
2026-10-07	Unavailable	Unavailable	2 / 1
2026-10-08	Unavailable	Unavailable	2 / 1
2026-10-09	Unavailable	Unavailable	2 / 1
2026-10-10	Unavailable	Unavailable	2 / 1
2026-10-11	Unavailable	Unavailable	2 / 1
2026-10-12	Unavailable	Unavailable	2 / 1
2026-10-13	Unavailable	Unavailable	2 / 1
2026-10-14	Unavailable	Unavailable	2 / 1
2026-10-15	Unavailable	Unavailable	2 / 1
2026-10-16	Unavailable	Unavailable	2 / 1
2026-10-17	Unavailable	Unavailable	2 / 1
2026-10-18	Unavailable	Unavailable	2 / 1
2026-10-19	Unavailable	Unavailable	2 / 1
2026-10-20	Unavailable	Unavailable	2 / 1
2026-10-21	Unavailable	Unavailable	2 / 1
2026-10-22	Unavailable	Unavailable	2 / 1
2026-10-23	Unavailable	Unavailable	2 / 1
2026-10-24	Unavailable	Unavailable	2 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	4	1
2026-06-01	4	1
2026-07-01	4	1
2026-08-01	4	1
2026-09-01	4	1
2026-10-01	4	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

share buybacks and CAPEX near $55MDirect metric needs a verified mapping
EPS near $2.7 next quarterDiluted EPS: $1.45 per share
net sales growth near 8% YoYRevenue growth: -8.17%
PE ratio below 13P/E (TTM): 13.25x

Next proof point

Nov 23, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.8%Typical daily move · historical

Downside history

-17.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Central Garden & Pet Company (Class A) outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a consumer-staples business with a mixed, execution-dependent thesis rather than a clear durable-growth story. The long-term thesis is intact, but the overall signal has shifted from mildly favorable to mixed.

What's priced into Central Garden & Pet Company (Class A)

CENTA is classified as cheap versus peers, and the expectations gap is close to neutral. The priced-in assessment is justified, with low fragility, so the evidence does not point to an especially fragile setup based on expectations.

What the fundamentals likely do

Near term, recent financial performance is strong, and management has consistently reaffirmed fiscal 2026 non-GAAP diluted EPS guidance of $2.70 or better; reported quarterly diluted EPS rose from $0.11 in the first quarter to $1.28 in the second. Capital spending is broadly aligned with stated plans, while the planned acquisition of about 80% of TRIXIE is still pending and the president transition adds a change to monitor. The next guidance update and weak jobs data are risks, despite a low estimated miss probability.

What Central Garden & Pet Company (Class A) hinges on

Over the next few quarters, the thesis depends on management maintaining guidance and continuing to deliver on earnings, alongside disciplined capital spending. Over the multi-year view, the European expansion depends on completing the TRIXIE acquisition and executing it; continued earnings strength at sector peers could also support the backdrop, while weaker employment or a guidance cut would weaken it.

Bottom line

For the next 1 to 3 years, CENTA’s long-term thesis is intact but mixed: recent results support it, while guidance, execution, and the pending European expansion remain important tests. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q1
Revenue	—	584M
EPS	—	0.13
FY 2026 · Annual
EPS	At least $2.7non-GAAP	—
Capital expenditure	$50M–$60M	—
FY 2027 · Annual
Revenue	—	2.94B
EPS	—	3.142
FY 2028 · Annual
Revenue	—	3.19B
EPS	—	3.321

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-27 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-28	Unavailable	Unavailable	2 / 1
2026-09-29	Unavailable	Unavailable	2 / 1
2026-09-30	Unavailable	Unavailable	2 / 1
2026-10-01	Unavailable	Unavailable	2 / 1
2026-10-02	Unavailable	Unavailable	2 / 1
2026-10-03	Unavailable	Unavailable	2 / 1
2026-10-04	Unavailable	Unavailable	2 / 1
2026-10-05	Unavailable	Unavailable	2 / 1
2026-10-06	Unavailable	Unavailable	2 / 1
2026-10-07	Unavailable	Unavailable	2 / 1
2026-10-08	Unavailable	Unavailable	2 / 1
2026-10-09	Unavailable	Unavailable	2 / 1
2026-10-10	Unavailable	Unavailable	2 / 1
2026-10-11	Unavailable	Unavailable	2 / 1
2026-10-12	Unavailable	Unavailable	2 / 1
2026-10-13	Unavailable	Unavailable	2 / 1
2026-10-14	Unavailable	Unavailable	2 / 1
2026-10-15	Unavailable	Unavailable	2 / 1
2026-10-16	Unavailable	Unavailable	2 / 1
2026-10-17	Unavailable	Unavailable	2 / 1
2026-10-18	Unavailable	Unavailable	2 / 1
2026-10-19	Unavailable	Unavailable	2 / 1
2026-10-20	Unavailable	Unavailable	2 / 1
2026-10-21	Unavailable	Unavailable	2 / 1
2026-10-22	Unavailable	Unavailable	2 / 1
2026-10-23	Unavailable	Unavailable	2 / 1
2026-10-24	Unavailable	Unavailable	2 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings